The U.S. FDA has approved #Onzetra
Xsail (sumatriptan nasal powder), an intranasal medication delivery system containing low-dose (22mg) #sumatriptan
powder, the most commonly prescribed medication for #migraine
A dose is delivered when the user exhales into the device, automatically closing the soft palate and sealing off the nasal cavity. Through a sealing nosepiece placed into the nostril, the exhaled breath carries medication from the device directly into one side of the nose and deep into the nasal cavity where absorption is efficient and consistent. Closure of the soft palate helps prevent swallowing and reduces GI absorption.